Literature DB >> 14695543

Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

Hiromi Fukushima-Uesaka1, Yoshiro Saito, Hidemi Watanabe, Kisho Shiseki, Mayumi Saeki, Takahiro Nakamura, Kouichi Kurose, Kimie Sai, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Sotaro Hanai, Toshiharu Nakajima, Kenji Matsumoto, Hirohisa Saito, Yu-ichi Goto, Hideo Kimura, Masaaki Katoh, Kenji Sugai, Narihiro Minami, Kuniaki Shirao, Tomohide Tamura, Noboru Yamamoto, Hironobu Minami, Atsushi Ohtsu, Teruhiko Yoshida, Nagahiro Saijo, Yutaka Kitamura, Naoyuki Kamatani, Shogo Ozawa, Jun-ichi Sawada.   

Abstract

In order to identify single nucleotide polymorphisms (SNPs) and haplotype frequencies of CYP3A4 in a Japanese population, the distal enhancer and proximal promoter regions, all exons, and the surrounding introns were sequenced from genomic DNA of 416 Japanese subjects. We found 24 SNPs, including 17 novel ones: two in the distal enhancer, four in the proximal promoter, one in the 5'-untranslated region (UTR), seven in the introns, and three in the 3'-UTR. The most common SNP was c.1026+12G>A (IVS10+12G>A), with a 0.249 frequency. Four non-synonymous SNPs, c.554C>G (p.T185S, CYP3A4(*)16), c.830_831insA (p.E277fsX8, (*)6), c.878T>C (p.L293P, (*)18), and c.1088 C>T (p.T363M, (*)11) were found with frequencies of 0.014, 0.001, 0.028, and 0.002, respectively. No SNP was found in the known nuclear transcriptional factor-binding sites in the enhancer and promoter regions. Using these 24 SNPs, 16 haplotypes were unambiguously identified, and nine haplotypes were inferred by aid of an expectation-maximization-based program. In addition, using data from 186 subjects enabled a close linkage to be found between CYP3A4 and CYP3A5 SNPs, especially among the SNPs at c.1026+12 in CYP3A4 and c.219-237 (IVS3-237, a key SNP site for CYP3A5(*)3), c.865+77 (IVS9+77) and c.1523 in CYP3A5. This result suggested that CYP3A4 and CYP3A5 are within the same gene block. Haplotype analysis between CYP3A4 and CYP3A5 revealed several major haplotype combinations in the CYP3A4-CYP3A5 block. Our findings provide fundamental and useful information for genotyping CYP3A4 (and CYP3A5) in the Japanese, and probably Asian populations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695543     DOI: 10.1002/humu.9210

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  48 in total

1.  Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.

Authors:  Lin Zhu; Jing Zhang; Hongtao Song; Qinghua Wang; Jianming Tan; Weizhen Wu; Meiqin Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

Review 4.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects.

Authors:  Yong Zeng; Yi-jing He; Fu-yuan He; Lan Fan; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

Review 6.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 7.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

8.  Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ho-Ching Chiu; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  World J Hepatol       Date:  2013-11-27

9.  Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.

Authors:  Ling Song; Yi Zhang; Ji Jiang; Shuang Ren; Li Chen; Dongyang Liu; Xijing Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

10.  CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.

Authors:  Wei Zhang; Yan-Zi Chang; Quan-Cheng Kan; Li-Rong Zhang; Zhi-Song Li; Hui Lu; Zhong-Yu Wang; Qin-Jun Chu; Jie Zhang
Journal:  Eur J Clin Pharmacol       Date:  2009-09-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.